As Gilead and Galapagos prepare their JAK inhibitor filgotinib for a US filing in rheumatoid arthritis, the drug has suffered some setbacks in mid-stage trials. Studies of the would-be rival to ...

Filgotinib is a n oral janus kinase (JAK1) inhibitor, and could compete with Pfizer’s class rival Xeljanz (tofacitinib) if approved in ulcerative colitis, as well as injected anti-TNF drugs such ...

Trial reveals filgotinib's potential to redefine Crohn’s disease treatment by delivering sustained remission and improved safety outcomes for patients worldwide. Study: Efficacy and safety of ...

虽然遭到退货，但是Galapagos仍将filgotinib作为核心管线开发，后来找到了新买家吉利德。2015年12月，吉利德以7.25亿美元首付款+13.5亿美元的里程碑金额获得了filgotinib共同开发和商业化权益。